title: Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
abstract: To enhance the delivery of rhGAA (recombinant GAA, where GAA stands for acid alpha-glucosidase) to the affected muscles in Pompe disease, the carbohydrate moieties on the enzyme were remodelled to exhibit a high affinity ligand for the CI-MPR (cation-independent M6P receptor, where M6P stands for mannose 6-phosphate). This was achieved by chemically conjugating on to rhGAA, a synthetic oligosaccharide ligand bearing M6P residues in the optimal configuration for binding the receptor. The carbonyl chemistry used resulted in the conjugation of approx. six synthetic ligands on to each enzyme. The resulting modified enzyme [neo-rhGAA (modified recombinant human GAA harbouring synthetic oligosaccharide ligands)] displayed near-normal specific activity and significantly increased affinity for the CI-MPR. However, binding to the mannose receptor was unaffected despite the introduction of additional mannose residues in neo-rhGAA. Uptake studies using L6 myoblasts showed neo-rhGAA was internalized approx. 20-fold more efficiently than the unmodified enzyme. Administration of neo-rhGAA into Pompe mice also resulted in greater clearance of glycogen from all the affected muscles when compared with the unmodified rhGAA. Comparable reductions in tissue glycogen levels in the Pompe mice were realized using an approx. 8-fold lower dose of neo-rhGAA in the heart and diaphragm and an approx. 4-fold lower dose in the skeletal muscles. Treatment of older Pompe mice, which are more refractory to enzyme therapy, with 40 mg/kg neo-rhGAA resulted in near-complete clearance of glycogen from all the affected muscles as opposed to only partial correction with the unmodified rhGAA. These results demonstrate that remodelling the carbohydrate of rhGAA to improve its affinity for the CI-MPR represents a feasible approach to enhance the efficacy of enzyme replacement therapy for Pompe disease.
authors.affiliation: Genzyme Corporation, 31 New York Avenue, Framingham, MA 01701-9322, USA.
authors.forename: Yunxiang
authors.initials: Y
authors.lastname: Zhu
authors.forename: Xuemei
authors.initials: X
authors.lastname: Li
authors.forename: Alison
authors.initials: A
authors.lastname: McVie-Wylie
authors.forename: Canwen
authors.initials: C
authors.lastname: Jiang
authors.forename: Beth L
authors.initials: BL
authors.lastname: Thurberg
authors.forename: Nina
authors.initials: N
authors.lastname: Raben
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Mattaliano
authors.forename: Seng H
authors.initials: SH
authors.lastname: Cheng
mesh_terms: D000375:Aging; D000818:Animals; D005087:Glucan 1,4-alpha-Glucosidase / Q000737:chemistry* / Q000378:metabolism* / Q000627:therapeutic use; D006003:Glycogen / Q000378:metabolism; D006009:Glycogen Storage Disease Type II / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice; D015394:Molecular Structure; D018482:Muscle, Skeletal / Q000201:enzymology / Q000378:metabolism*; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism; D009844:Oligosaccharides; D011485:Protein Binding; D017527:Receptor, IGF Type 2 / Q000737:chemistry / Q000378:metabolism*; D011994:Recombinant Proteins; D000520:alpha-Glucosidases
chemical_list: D009844:Oligosaccharides; D017527:Receptor, IGF Type 2; D011994:Recombinant Proteins; D006003:Glycogen; D000520:alpha-Glucosidases; D005087:Glucan 1,4-alpha-Glucosidase